Panasonic and Institute of Microchemical Technology Co., Ltd. Jointly Develop Mass Production Technology for Microfluidic Devices by Glass Molding, a First in the Industry*1
6.11.2019 05:17:00 EET | Business Wire | Press release
Panasonic Corporation (Panasonic) and Institute of Microchemical Technology Co., Ltd. (IMT) jointly developed a technology for mass production of microfluidic devices*2 using a glass molding. Compared to the conventional glass etching method, this technology realizes low cost (about 1/10) and highly accurate (about 10 times) mass production. These devices can be applied to sensing and analysis for medical, biological, environmental (water and air quality) applications, etc. The companies will start accepting prototype orders from FY2019, and are planning to start mass production from FY2020. Panasonic and IMT will present and exhibit this device at the 40th meeting of Society for Chemistry and Micro-Nano Systems (CHEMINAS 40th) held at Act City Hamamatsu in Hamamatsu City, Shizuoka Prefecture, Japan from November 19th to 21st.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191105006302/en/
Microfluidic device technology (Graphic: Business Wire)
[Effect]
Conventional glass microfluidic devices have not been widely used, because of high cost and poor precision. This development achieved mass production and cost reduction of glass microfluidic devices by combining IMT's microfluidic device design technology and Panasonic's glass molding technology. As a result, disposable use of glass microfluidic devices becomes possible. In addition, by realizing high precision, it is easy to incorporate the device as a part of equipment and systems.
[Application]
By taking advantage of the environmental and chemical resistance of glass microfluidic devices, it can be applied to environmental sensing, blood testing, and pharmaceutical equipment as disposable detection devices for analysis and testing in outdoor and harsh environments.
[Characteristic]
The newly developed microfluidic device has the following features.
1. Up to φ50mm size
2. More than 10,000 devices per month of production capacity
3. Manufacturing process with the shape precision of about 1μm
[Technology]
This development is realized by the following technologies.
(1) Design and interface technology of microfluidic device optimized for glass molding
(2) Microstructure mold processing technology to higher hardness material and microstructural glass molding technology to precisely transfer to glass
(3) Thermal bonding technology to join a flat glass plate and a plate with microstructures.
Notes:
*1: As of November 6, 2019, Panasonic survey
*2: A device that can perform various chemical processes (mixing, reaction, extraction, synthesis, detection) in a minute flow path with a small amount and high efficiency by flowing liquid through a groove with a width and depth of several hundreds of micrometers.
[Background]
General microfluidic device made of glass used in microfluidics technology [1] is mainly produced by etching techniques. After drawing the flow path pattern by photolithography, the glass flow path is formed by etching, and the cover glass with the machined introduction hole is bonded. Since the inception of this field, IMT has provided high-level products as a pioneer in the planning, design and manufacture of glass microfluidic devices. However, in addition to the skill required for manual manufacturing, the manufacturing process took several months. For this reason, the manufacturing time and cost per piece became a hurdle, and generalization and industrial mounting were not realized, and the use was limited mainly to basic research applications.
On the other hand, Panasonic has been developing and manufacturing glass molding technology [2] from the 1980s, that has contributed to the commercialization of the world's highest level of optical device. They are used in lenses for various optical devices, like digital still cameras.
By combining Panasonic's glass molding technology and IMT design technology, it became possible to develop microstructure mold machining technology, molding technology, and joining technology suitable for mass production of microfluidic devices using glass molding technology. The companies have succeeded in developing mass production technology for microfluidic devices. As a result, it is possible to reduce the cost to about 1/10 compared to the conventional manufacturing method, and to supply glass microfluidic devices with improved precision 10 times or more in less than half the delivery time.
[Practical realization]
With the development of mass production technology for microfluidic devices [3] using this glass molding technology, glass microfluidic devices are widely used as disposable detection devices for analysis and testing in outdoor and harsh environments, and for disposable devices for blood testing equipment.
[Explanation of terms]
[1] Microfluidic device technology
This technology integrates chemical processes such as mixing, reaction, separation, extraction, synthesis, and detection in a flow channel of several tens to several hundreds of μm created on a substrate (microfluidic device) of several cm square. By freely integrating chemical processes that have been performed in laboratories and factories in the microspace of microfluidic devices, it becomes possible to use energy and space much more efficiently. It is expected to contribute greatly to the evolution of chemical technology in the future. This chemical process integration technology (microfluidic technology) in the micro space was established as a result of research and development of the Kitamori “Integrated Chemistry” project. The project was carried out at Kitamori Lab., Department of Applied Chemistry, School of Engineering, The University of Tokyo, and Kanagawa Academy of Science and Technology (currently Kanagawa Institute of Industrial Science and Technology).
[2] Glass molding technology (mold machining technology, mold protection coating technology, molding technology)
[3] Application examples of microfluidic devices using glass molding technology
About Panasonic
Panasonic Corporation is a worldwide leader in the development of diverse electronics technologies and solutions for customers in the consumer electronics, housing, automotive, and B2B businesses. The company, which celebrated its 100th anniversary in 2018, has expanded globally and now operates 582 subsidiaries and 87 associated companies worldwide, recording consolidated net sales of 8.003 trillion yen for the year ended March 31, 2019. Committed to pursuing new value through innovation across divisional lines, the company uses its technologies to create a better life and a better world for its customers. To learn more about Panasonic: https://www.panasonic.com/global.
About Institute of Microchemical Technology
IMT is a pioneer company of microchemical chip technology (microfluidics) and was founded in 2001 as a venture company of the University of Tokyo and Kanagawa Institute of Industrial Science and Technology (formerly Kanagawa Academy of Science and Technology).
IMT manufactures and sells microchemical chips, their peripheral equipment and system devices.
Company Name: Institute of Microchemical Technology Co., Ltd (IMT)
Capital: 100M JPY
Foundation: May 1st, 2001
Address: A-19 AIRBIC, 7-7 Shinkawasaki, Saiwai, Kawasaki, Kanagawa 212-0032 Japan
TEL: +81-44-201-9889 FAX: +81-44-201-9890
HP: https://www.i-mt.co.jp/en/
Source: https://news.panasonic.com/global/press/data/2019/11/en191106-3/en191106-3.html
Related Links
Industrial Devices & Solutions - Panasonic
https://industrial.panasonic.com/ww
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191105006302/en/
Contact information
Panasonic
Innovation Strategy Office
Technology Public Relations Section
crdpress@ml.jp.panasonic.com
[Inquiries for prototypes]
Institute of Microchemical Technology Co., Ltd.
Email:info@i-mt.co.jp Tel: +81-44-201-9889
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Acceleronix, IDEMIA Secure Transactions and Orange Announce Flexible, Single-SKU Manufacturing with Quantum-Safe IFPP4.11.2026 17:44:00 EET | Press release
Orange, one of the world’s leading telecom operators, has joined the global quantum-safe In-Factory Profile Provisioning (IFPP) program, jointly launched by Acceleronix and IDEMIA Secure Transactions at MWC Barcelona in February. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104070181/en/ Acceleronix, IDEMIA Secure Transactions and Orange announce flexible, single-SKU manufacturing with quantum-safe IFPP The program enables device makers to build a single product for every market and connect it to the Orange network before it leaves the factory. Acceleronix and IDEMIA Secure Transactions will demonstrate the solution live at electronica 2026, the international electronics trade fair, at Messe München, Hall C2, Stand 601, from 10 to 13 November. Most connected devices share the same weak spot: provisioning and testing on the production line. In-Factory Profile Provisioning (IFPP) addresses this challenge by enabling conne
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 16:13:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of disease progression or death compared with standard chemoimmunotherapy. Full results from the MANGROVE study will be presented during the Plenary Scientific Session at the 68th American Society of Hematology (ASH) Annual Meeting on December 13, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261103605806/en/ BeOne Medicines' flagship U.S. manufacturing and clinical R&D facility at the P
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 16:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstracts at the 2026 American Society of Hematology (ASH) Annual Meeting, to beheld December 12 – 15, 2026, in New Orleans. “Our ASH presentations demonstrate meaningful progress across our Hematology portfolio to advance novel treatment approaches for people with serious hematologic conditions,” said Pablo J. Cagnoni, M.D., President, Incyte and Global Head of Research and Development. "We are particularly encouraged by the continued clinical progress of INCA033989 in myelofibrosis (MF) and essential thrombocythemia (ET) and the data for latarcibart in von Willebrand disease (VWD) - data that support our goal of advancing differentiated medicines with the potential to meaningfully improve outcomes for patients." Details on key data presentations at ASH include: Oral Presentations INCA033989 (mutCALR) In JAK-Inhibitor Naive Patients with Myelof
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 16:00:00 EET | Press release
Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMware and IBM environments, without having to go through a lengthy individual tender process. Through Rimini Support™, organizations gain access to a support alternative enabling them to significantly reduce their historical support costs, improve service quality and support respons
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 16:00:00 EET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
